Relationship Between Metabolic Syndrome and Beta-Cell Function in Nondiabetic Korean Premenopausal and Postmenopausal Women: 2015 Korean National Health and Nutrition Examination Survey
Restricted accessResearch articleFirst published online February, 2020
Relationship Between Metabolic Syndrome and Beta-Cell Function in Nondiabetic Korean Premenopausal and Postmenopausal Women: 2015 Korean National Health and Nutrition Examination Survey
This study was conducted to assess the relationship between metabolic syndrome (MetS) and beta-cell function in nondiabetic Korean women.
Methods:
This study included 2,507 women (premenopausal women, 1,359; postmenopausal women, 1,148) who were aged ≥20 and used 2015 Korean National Health and Nutrition Examination Survey (KNHANES) data.
Results:
Key study results were as follows: first, in both premenopausal and postmenopausal women, after adjusting for related variables [except body mass index (BMI)], MetS (P < 0.001) and metabolic syndrome score (MSS; P < 0.001) were positively associated with the homeostasis model assessment of beta-cell function (HOMA-B) levels. Second, in premenopausal women, when further adjusted for BMI, MetS (P = 0.002) and MSS (P < 0.001) were also positively associated with HOMA-B levels. However, in postmenopausal women, when further adjusting for BMI, the associations of MetS (P = 0.322) or MSS (P = 0.855) and HOMA-B levels were no longer significant.
Conclusions:
Metabolic syndrome was positively associated with beta-cell function in nondiabetic Korean premenopausal women, but not in Korean postmenopausal women.
Get full access to this article
View all access options for this article.
References
1.
ReavenGM. Role of insulin resistance in human disease. Diabetes, 1988; 37:1598–1607.
2.
RaimundoM, LopesJA. Metabolic syndrome, chronic kidney disease, and cardiovascular disease: A dynamic and life-threatening triad. Cardiol Res Pract, 2011; 2011:747861.
3.
PorteD. Clinical importance of insulin secretion and its interaction with insulin resistance in the treatment of type 2 diabetes mellitus and its complications. Diabetes Metab Res Rev, 2001; 17:181–188.
4.
LeahyJL. Pathogenesis of type 2 diabetes mellitus. Arch Med Res, 2005; 36:197–209.
5.
CnopM, VidalJ, HullRL, et al.Progressive loss of beta-cell function leads to worsening glucose tolerance in first-degree relatives of subjects with type 2 diabetes. Diabetes Care, 2007; 30:677–682.
6.
DalalPK, AgarwalM. Postmenopausal syndrome. Indian J Psychiatry, 2015; 57:S222–S232.
7.
MaasAH, FrankeHR. Women's health in menopause with a focus on hypertension. Neth Heart J, 2009; 17:68–72.
8.
KimC, KongS, LaughlinGA, et al.Endogenous sex hormone changes in postmenopausal women in the diabetes prevention program. J Clin Endocrinol Metab, 2012; 97:2853–2861.
9.
CheungKL, StefanickML, AllisonMA, et al.Menopausal symptoms in women with chronic kidney disease. Menopause, 2015; 22:1006–1011.
10.
GurkaMJ, VishnuA, SantenRJ, et al.Progression of metabolic syndrome severity during the menopausal transition. J Am Heart Assoc, 2016; 5:e003609.
11.
AshrafMS, VongpatanasinW. Estrogen and hypertension. Curr Hypertens Rep, 2006; 8:368–376.
12.
BakerL, MeldrumKK, WangM, et al.The role of estrogen in cardiovascular disease. J Surg Res, 2003; 115:325–344.
13.
GluhovschiG, GluhovschiA, AnastasiuD, et al.Chronic kidney disease and the involvement of estrogen hormones in its pathogenesis and progression. Rom J Intern Med, 2012; 50:135–344.
14.
SalpeterSR, WalshJM, OrmistonTM, et al.Meta-analysis: Effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab, 2006; 8:538–554.
15.
van der MoorenMJ, KenemansP. Postmenopausal hormone therapy: Impact on menopause-related symptoms, chronic disease and quality of life. Drugs, 2004; 64:821–836.
16.
YoonH, KimSG, KimGS, et al.Relationship between metabolic syndrome and metabolic syndrome score and insulin resistance and beta cell function in Korean adults with type 2 diabetes mellitus. Acta Medica Mediterr, 2016; 32:1697–1704.
17.
YoonH, JeongDK, LeeKS, et al.Relationship between metabolic syndrome and metabolic syndrome score and beta cell function by gender in Korean populations with obesity. Endocr J, 2016; 63:785–793.
18.
ScraggR, SowersM, BellC. Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the Third National Health and Nutrition Examination Survey. Diabetes Care, 2004; 27:2813–2818.
19.
MatthewsDR, HoskerJP, RudenskiAS, et al.Homeostasis model assessment: Insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 1985; 28:412–419.
20.
Revised NCEP-ATP III based on common clinical measures Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA, 2001; 285:2486–2497.
21.
WHO. Western Pacific Region. International Association for the Study of Obesity Task Force. The Asia-Pacific Perspective: Redefining Obesity and its Treatment. Sydney: Health Communications Australia; 2000: 15–21.
22.
YoonH, KimGS, KimSG, et al.The relationship between metabolic syndrome and increase of metabolic syndrome score and serum vitamin D levels in Korean adults: 2012 Korean National Health and Nutrition Examination Survey. J Clin Biochem Nutr, 2015; 57:82–87.
23.
LinWY, YangWS, LeeLT, et al.Insulin resistance, obesity, and metabolic syndrome among non-diabetic pre- and post-menopausal women in North Taiwan. Int J Obes (Lond), 2006; 30:912–917.
24.
ChenCH, LinKC, TsaiST, et al.Different association of hypertension and insulin-related metabolic syndrome between men and women in 8437 nondiabetic Chinese. Am J Hypertens, 2000; 13:846–853.
25.
HuG, QiaoQ, TuomilehtoJ, et al.Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med, 2004; 164:1066–1076.
26.
SinclairKA, BogartA, BuchwaldD, et al.The prevalence of metabolic syndrome and associated risk factors in Northern Plains and Southwest American Indians. Diabetes Care, 2011; 34:118–120.
27.
YihuaL, YunJ, DongshenZ. Coronary artery disease in premenopausal and postmenopausal women. Int Heart J, 2017; 58:174–179.
28.
PardheBD, PathakS, BhetwalA, et al.Effect of age and estrogen on biochemical markers of bone turnover in postmenopausal women: A population-based study from Nepal. Int J Womens Health, 2017; 9:781–788.
29.
DavisonS, DavisSR. New markers for cardiovascular disease risk in women: Impact of endogenous estrogen status and exogenous postmenopausal hormone therapy. J Clin Endocrinol Metab, 2003; 88:2470–2478.
30.
GupteAA, PownallHJ, HamiltonDJ. Estrogen: An emerging regulator of insulin action and mitochondrial function. J Diabetes Res, 2015; 2015:916585.
31.
MunozJ, DerstineA, GowerBA. Fat distribution and insulin sensitivity in postmenopausal women: Influence of hormone replacement. Obes Res, 2002; 10:424–431.
32.
IhmSH, MatsumotoI, SawadaT, et al.Effect of donor age on function of isolated human islets. Diabetes, 2006; 55:1361–1368.
33.
SzokeE, ShrayyefMZ, MessingS, et al.Effect of aging on glucose homeostasis: Accelerated deterioration of beta-cell function in individuals with impaired glucose tolerance. Diabetes Care, 2008; 31:539–543.
34.
ZirilliL, RochiraV, DiazziC, et al.Human models of aromatase deficiency. J Steroid Biochem Mol Biol, 2008; 109:212–218.
35.
YuchiY, CaiY, LegeinB, et al.Estrogen receptor α regulates β-cell formation during pancreas development and following injury. Diabetes, 2015; 64:3218–3228.
36.
ZhouZ, RibasV, RajbhandariP, et al.Estrogen receptor α protects pancreatic β-cells from apoptosis by preserving mitochondrial function and suppressing endoplasmic reticulum stress. J Biol Chem, 2018; 293:4735–4751.
37.
Karvonen-GutierrezC, KimC. Association of mid-life changes in body size, body composition and obesity status with the menopausal transition. Healthcare (Basel), 2016; 4:E42.
38.
TchernofA, PoehlmanET, DesprésJP. Body fat distribution, the menopause transition, and hormone replacement therapy. Diabetes Metab, 2000; 26:12–20.
39.
TothMJ, TchernofA, SitesCK, et al.Menopause-related changes in body fat distribution. Ann N Y Acad Sci, 2000; 904:502–506.
40.
UtzschneiderKM, CarrDB, HullRL, et al.Impact of intra-abdominal fat and age on insulin sensitivity and beta-cell function. Diabetes, 2004; 53:2867–2872.
41.
SuminoH, IchikawaS, YoshidaA, et al.Effects of hormone replacement therapy on weight, abdominal fat distribution, and lipid levels in Japanese postmenopausal women. Int J Obes Relat Metab Disord, 2003; 27:1044–1051.
42.
CollinsP, RosanoG, CaseyC, et al.Management of cardiovascular risk in the perimenopausal women: A consensus statement of European cardiologists and gynecologists. Climacteric, 2007; 10:508–526.
43.
StatanMA, SternMP, MillerWG, et al.Insulin assay standardization. Diabetes Care, 2010; 33:205–206.
